Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Pfizer Wants to Do Deals in Emerging Markets

publication date: Jun 19, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Pfizer will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China. Currently, Pfizer occupies the number three position. The emerging markets sector is worth $80 billion currently, and is expected to grow to $120 billion by 2012. Asked if acquisitions figured in the company’s future, Jean-Michel Halfon, President of Emerging Markets for Pfizer replied, "We see opportunities coming from the financial crisis ... opportunities to build partnerships in emerging markets." More details...

Stock Symbol: (NYSE: PFE)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...